Non-Hodgkin’s Lymphomas, Version 1.2013

View More View Less
  • 1 From Memorial Sloan-Kettering Cancer Center; The University of Texas MD Anderson Cancer Center; Massachusetts General Hospital Cancer Center; Stanford Cancer Institute; UCSF Helen Diller Family Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Alabama at Birmingham Comprehensive Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Roswell Park Cancer Institute; Huntsman Cancer Institute at the University of Utah; Duke Cancer Institute; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Consultant; Dana-Farber/Brigham and Women’s Cancer Center; City of Hope Comprehensive Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Fox Chase Cancer Center; Vanderbilt-Ingram Cancer Center; Moffitt Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Michigan Comprehensive Cancer Center; UNMC Eppley Cancer Center at The Nebraska Medical Center; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.
Restricted access

These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Non-Hodgkin’s Lymphomas (NHL) and provide a discussion of the clinical evidence that support the updates. The updates discussed in this article feature recommendations for additional treatment options in patients with chronic lymphocytic leukemia and guidance surrounding the management of hepatitis virus reactivation/infections in high-risk patients with NHL undergoing antitumor therapy.

Supplementary Materials

    • Supplemental Material (PDF 921 KB)
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 390 189 8
PDF Downloads 78 51 6
EPUB Downloads 0 0 0